Vendor Intelligence Report: M-Peptides

Published 13 Jun 2026. 26-page investigative report on who is behind M-Peptides: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 20 Finnrick lab tests, M-Peptides has 14 passes and 6 fails, for an overall pass rate of 70%. The catalog record is small, with only tirzepatide and retatrutide in Finnrick's current dataset, and it is not evenly distributed: tirzepatide is the stronger side, while retatrutide is the caution line, with failures matching passes and an RT-15 fill-quantity warning in the underlying file. Ratings also contract under stricter scoring, and no endotoxin data was identified.

The non-lab investigation makes MPS look less like a conventional lab vendor and more like a platform-native China-origin seller operating through Discord, Telegram and GLP-1 Forum. The only consistent public operator is Elsa; no surname, registered legal entity, public warehouse address or manufacturer identity was identified in the records reviewed. That opacity matters because the buyer's practical counterparty is an email address, a forum account and a crypto transaction.

The infrastructure trail is the sharper hook. The older mps-m.com contact trail is now a parked domain with prior use by an unrelated Moscow construction-equipment company; live ordering instead runs through m-mps.com as a WooCommerce storefront dressed as M Beads. Bracelet SKUs map to peptide batch codes, and the refund policy breaks cover with research-compound language. Add expired Discord invites, anti-impersonation warnings, crypto-only payments and a Canada warehouse opened after a Health Canada advisory, and verification/recovery become product-specific risk controls rather than administrative details.

Inside the full report:

  • Per-product pass/fail rates, rating trajectories and methodology-divergence charts for both Finnrick-tested products
  • Domain-history timeline for mps-m.com, certificate-transparency records and the prior MashPromStroy-M Wayback capture
  • Evidence walk-through of the M Beads WooCommerce cover storefront, bracelet SKUs and refund-policy language
  • Operator/contact map covering Elsa, entity-search dead ends, GLP-1 Forum, Discord, Telegram, stale invites and current-channel verification
  • Janoshik ID and batch-code/cap-color analysis, plus after-sales and crypto-payment recourse review
  • Jurisdiction risk analysis covering CBP category seizures, the Health Canada advisory and the Canada warehouse timeline

Risk assessment

  • Retatrutide quality-reliability risk — high: Retatrutide is 8 Finnrick tests with 4 pass / 4 fail and a 69.65% rating; records also identify an RT-15 fill-quantity concern.
  • Canada regulatory and seizure risk — high: Canada warehouse opened 57 days after Health Canada RA-81874 warned on the same peptide compounds in MPS's catalog.
  • Endotoxin-testing gap — medium: No endotoxin or sterility data identified for any injectable MPS batch; identity/purity COAs do not answer this risk.
  • Operator and corporate opacity risk — medium: Only public operator is Elsa; no surname, registered legal entity, address, warehouse operator or manufacturer was identified.
  • Stealth-commerce and payment-recourse risk — medium: Ordering site presents as M Beads jewelry and accepts crypto-only; disputes depend on a Janoshik-only vendor policy, not chargebacks.
  • Impersonation and brand-confusion risk — medium: Repeated scam warnings, expired Discord invites and old/current email-domain mismatch require strict channel verification.
  • US import/customs disruption risk — medium: CBP Cincinnati seized 5,000+ China peptide shipments in MPS product categories; U.S. warehouse lowers doorstep risk but not replenishment risk.